Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Outlook Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Outlook Therapeutics Inc
Rating: 0.58100
Author: Trendlyne DVM scores

about

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

0.25 0.03 (13.64%)

91.72% Fall from 52W High

2.1M

XNAS Volume

XNAS 10 Apr, 2026 5:30 PM (EDT)

Not Eligible

Expensive Valuation

2.0 / 100

Technically Bearish

21.2 / 100

1Yr Price target upside is 1568%

3 analysts

Outlook Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

91.72% Fall from 52W High

SWOT Analysis

Outlook Therapeutics Inc Live Price Chart